Methylpromazine

CHEMBL829 Phase 4 Aprovado Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

298.4 g/mol

LogP

4.7

Phase

4

This phenothiazine derivative with sedative and antiemetic properties was used as an antipsychotic and to prevent nausea and vomiting, working by blocking dopamine receptors in the brain. It is one of many phenothiazine compounds that vary in their potency and side effect profiles.

Peso Molecular

298,4000 g/mol

LogP

4,70

TPSA

31,80 Å²

Regra dos 5 de Lipinski

Aprovado

Mecanismo de Ação

Blocks dopamine D2 receptors in the mesolimbic pathway, reducing excessive dopaminergic neurotransmission associated with psychotic symptoms. Many also antagonize serotonin 5-HT2A receptors, which may improve negative symptoms and reduce extrapyramidal side effects.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mecanismo

Blocks dopamine D2 receptors in the mesolimbic pathway, reducing excessive dopaminergic neurotransmission associated with psychotic symptoms. Many also antagonize serotonin 5-HT2A receptors, which may improve negative symptoms and reduce extrapyramidal …

Estrutura 2D

SVG PNG

Cite this structure

Embed this structure

SMILES

CC(CN(C)C)CN1c2ccccc2Sc2ccccc21

InChI

InChI=1S/C18H22N2S/c1-14(12-19(2)3)13-20-15-8-4-6-10-17(15)21-18-11-7-5-9-16(18)20/h4-11,14H,12-13H2,1-3H3

Molecular Formula

C18H22N2S

HBD / HBA

- / 3

Ligações Rotacionáveis

4

Átomos Pesados

21

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Perguntas frequentes

This phenothiazine derivative with sedative and antiemetic properties was used as an antipsychotic and to prevent nausea and vomiting, working by blocking dopamine receptors in the brain. It is one of many phenothiazine compounds that vary in their potency and side effect profiles.

Blocks dopamine D2 receptors in the mesolimbic pathway, reducing excessive dopaminergic neurotransmission associated with psychotic symptoms. Many also antagonize serotonin 5-HT2A receptors, which may improve negative symptoms and reduce extrapyramidal side effects.

Yes, Methylpromazine is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL829. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 5574. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

PillFYI

Procura informações acessíveis para o paciente?

Methylpromazine no PillFYI

Estrutura

Dados Rápidos

Fórmula: C18H22N2S

Links Externos

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Aviso Médico

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.